Hepatitis C virus: Current steps toward elimination in Germany and barriers to reaching the 2030 goal

被引:7
|
作者
Sarrazin, Christoph [1 ,2 ,3 ]
Boesecke, Christoph [4 ,5 ]
Golsabahi-Broclawski, Solmaz [6 ]
Moog, Gero [7 ]
Negro, Francesco [8 ,9 ,10 ]
Silaidos, Carmina [11 ]
Patel, Polly [12 ]
Lohmann, kristina [11 ]
Spinner, Christoph D. [13 ,14 ]
Walcher, Stephan [15 ]
Wedemeyer, Heiner [16 ,17 ]
Woerns, Marcus-Alexander [18 ,19 ]
机构
[1] Goethe Univ Hosp Frankfurt, Dept Internal Med, Frankfurt, Germany
[2] Goethe Univ Hosp Frankfurt, St Josefs Hosp Wiesbaden, Liver Ctr, Frankfurt, Germany
[3] Goethe Univ Hosp Frankfurt, Viral Hepatitis Res Grp, Frankfurt, Germany
[4] Univ Hosp Bonn, Dept Med 1, Bonn, Germany
[5] German Ctr Infect Res DZIF, Partner Site Bonn Cologne, Bonn, Germany
[6] Med Inst Transcultural Med, Bielefeld, Germany
[7] Gastroenterol Praxis Marienkrankenhaus, Kassel, Germany
[8] Geneva Univ Hosp, Div Gastroenterol, Geneva, Switzerland
[9] Geneva Univ Hosp, Div Hepatol, Geneva, Switzerland
[10] Geneva Univ Hosp, Div Clin Pathol, Geneva, Switzerland
[11] AbbVie Deutschland GmBH Co KG, Wiesbaden, Germany
[12] AbbVie Inc, N Chicago, IL USA
[13] Tech Univ Munich, Univ Hosp Rechts Isar, Sch Med, Dept Internal Med 2, Munich, Germany
[14] German Ctr Infect Res DZIF, Partner Site Munich, Munich, Germany
[15] CONCEPT, Ctr Addict Med, Munich, Germany
[16] Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, Hannover, Germany
[17] Leberstiftungs GmbH Deutschland, Hannover, Germany
[18] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Med 1, Mainz, Germany
[19] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Cirrhosis Ctr Mainz CCM, Mainz, Germany
关键词
barriers; elimination; Germany; Hepatitis C; high-risk groups; DIRECT-ACTING ANTIVIRALS; INJECT DRUGS; HCV; INFECTION; PREVALENCE; PEOPLE; RISK; EPIDEMIOLOGY; MANAGEMENT; EFFICACY;
D O I
10.1002/hsr2.290
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Hepatitis C virus (HCV) affects over 70 million people globally, with an estimated 399 000 HCV-related deaths in 2016. The World Health Organization (WHO) has set a goal to eliminate HCV by 2030. Despite the availability of direct-acting antivirals-highly effective and well-tolerated therapies for HCV-many patients infected with HCV in Germany have not initiated treatment, including a majority of those who are aware of their positive diagnosis. Barriers to screening, diagnosis, and treatment are major factors taking many countries off track for HCV elimination by 2030. Identifying country-specific barriers and challenges, particularly in at-risk populations such as people who inject drugs or men who have sex with men, has the potential to create tailored programs and strategies to increase access to screening or treatment and engage at-risk populations. This review aims to report the current steps toward HCV elimination in Germany, the country-specific barriers and challenges that will potentially prevent reaching the 2030 HCV elimination goal and describe good practice examples to overcome these barriers.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] World hepatitis day in Burkina Faso, 2017: seroprevalence and vaccination against hepatitis B virus to achieve the 2030 elimination goal
    Diarra, Birama
    Yonli, Albert Theophane
    Ouattara, Abdoul Karim
    Zohoncon, Theodora Mahoukede
    Traore, Lassina
    Nadembega, Christelle
    Obiri-Yeboah, Dorcas
    Yara, Justine
    Pietra, Virginio
    Ouedraogo, Paul
    Bougouma, Alain
    Sanogo, Rokia
    Simpore, Jacques
    VIROLOGY JOURNAL, 2018, 15
  • [22] Meeting the WHO hepatitis C virus elimination goal: Review of treatment in paediatrics
    Kim, Nathan G.
    Kullar, Ravina
    Khalil, Haydar
    Saab, Sammy
    JOURNAL OF VIRAL HEPATITIS, 2020, 27 (08) : 762 - 769
  • [23] Toward ending hepatitis C virus infection: What are the next steps?
    Cadieux, Genevieve
    Sachdeva, Herveen
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2017, 189 (16) : E583 - E584
  • [24] Overcoming barriers to hepatitis C elimination
    Mendizabal, Manuel
    Alonso, Cristina
    Silva, Marcelo O.
    FRONTLINE GASTROENTEROLOGY, 2019, 10 (03) : 207 - 209
  • [25] Hepatitis C Elimination. Are we on course for 2030?
    Qureshi, Huma
    Arif, Ambreen
    ANNALS OF KING EDWARD MEDICAL UNIVERSITY LAHORE PAKISTAN, 2024, 30 (01): : 102 - 105
  • [26] Universal Screening for Hepatitis C Virus Infection A Step Toward Elimination
    Graham, Camilla S.
    Trooskin, Stacey
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 323 (10): : 936 - 937
  • [27] Elimination of hepatitis C in Australia by 2030: a decade and counting
    Dore, Gregory J.
    AUSTRALIAN PRESCRIBER, 2021, 44 (02) : 36 - 37
  • [28] Hepatitis C in sub-Saharan Africa: the current status and recommendations for achieving elimination by 2030
    Sonderup, Mark W.
    Afihene, Mary
    Ally, Reidwaan
    Apica, Betty
    Awuku, Yaw
    Cunha, Lina
    Dusheiko, Geoffrey
    Gogela, Neliswa
    Lohoues-Kouacou, Marie-Jeanne
    Lam, Phillip
    Lesi, Olufunmilayo
    Mbaye, Papa Saliou
    Musabeyezu, Emmanuel
    Musau, Betty
    Ojo, Olesegun
    Rwegasha, John
    Scholz, Barbara
    Shewaye, Abate B.
    Tzeuton, Christian
    Kassianides, Chris
    Spearman, C. Wendy
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2017, 2 (12): : 910 - 919
  • [29] Micro-elimination of hepatitis C virus infection in β-Thalassaemia major patients: Positively moving towards the World Health Organisation 2030 eradication goal
    Giannini, Edoardo G.
    Aghemo, Alessio
    DIGESTIVE AND LIVER DISEASE, 2019, 51 (04) : 568 - 569
  • [30] Progress toward hepatitis C virus elimination among people living with HIV-hepatitis C virus coinfection in Canada
    El Sheikh, Mariam Z.
    Young, Jim
    Panagiotoglou, Dimitra
    Cooper, Curtis
    Cox, Joseph
    Martel-Laferriere, Valerie
    Walmsley, Sharon
    Klein, Marina B.
    CANADIAN LIVER JOURNAL, 2025, 8 (01): : 49 - 62